Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 217 to 228 of 228 entries
Sorted by: Best Match Show Resources per page
Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature.

Nefrologia

Bover J, Bosch R, Górriz JL, Ureña P, Ortiz A, daSilva I, García-Trabanino RA, Hueso M, Trinidad P, Jara A, Furlano M, Gelpi R, Vila-Santandreu A, Restrepo CA, Sánchez-Baya M, Arana C, Goicoechea M, Coll V, Segura J, Gutiérrez O, Kalantar-Zadeh K, Sánchez E, Ferreiro A, García-Maset R.
PMID: 34452777
Nefrologia (Engl Ed). 2021 Aug 24; doi: 10.1016/j.nefro.2021.04.011. Epub 2021 Aug 24.

No abstract available.

Cite
Bover J, Bosch R, Górriz JL, et al. Los riñones también hablan español: iniciativas hacia la estandarización de nuestra nomenclatura nefrológica. Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. Nefrologia (Engl Ed). 2021;doi: 10.1016/j.nefro.2021.04.011.
Bover, J., Bosch, R., Górriz, J. L., Ureña, P., Ortiz, A., daSilva, I., García-Trabanino, R. A., Hueso, M., Trinidad, P., Jara, A., Furlano, M., Gelpi, R., Vila-Santandreu, A., Restrepo, C. A., Sánchez-Baya, M., Arana, C., Goicoechea, M., Coll, V., Segura, J., Gutiérrez, O., Kalantar-Zadeh, K., Sánchez, E., Ferreiro, A., & García-Maset, R. (2021). Los riñones también hablan español: iniciativas hacia la estandarización de nuestra nomenclatura nefrológica. Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. Nefrologia, . https://doi.org/10.1016/j.nefro.2021.04.011
Bover, Jordi, et al. "Los riñones también hablan español: iniciativas hacia la estandarización de nuestra nomenclatura nefrológica." Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. Nefrologia vol. (2021). doi: https://doi.org/10.1016/j.nefro.2021.04.011
Bover J, Bosch R, Górriz JL, Ureña P, Ortiz A, daSilva I, García-Trabanino RA, Hueso M, Trinidad P, Jara A, Furlano M, Gelpi R, Vila-Santandreu A, Restrepo CA, Sánchez-Baya M, Arana C, Goicoechea M, Coll V, Segura J, Gutiérrez O, Kalantar-Zadeh K, Sánchez E, Ferreiro A, García-Maset R. Los riñones también hablan español: iniciativas hacia la estandarización de nuestra nomenclatura nefrológica. Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. Nefrologia (Engl Ed). 2021 Aug 24; doi: 10.1016/j.nefro.2021.04.011. Epub 2021 Aug 24. Spanish. PMID: 34452777.
Copy Download .nbib Format: NLM
Succinate Pathway in Head and Neck Squamous Cell Carcinoma: Potential as a Diagnostic and Prognostic Marker.

Cancers

Terra X, Ceperuelo-Mallafré V, Merma C, Benaiges E, Bosch R, Castillo P, Flores JC, León X, Valduvieco I, Basté N, Cámara M, Lejeune M, Gumà J, Vendrell J, Vilaseca I, Fernández-Veledo S, Avilés-Jurado FX.
PMID: 33916314
Cancers (Basel). 2021 Apr 01;13(7). doi: 10.3390/cancers13071653.

Head and neck squamous cell carcinoma (HNSCC) is characterized by high rates of mortality and treatment-related morbidity, underscoring the urgent need for innovative and safe treatment strategies and diagnosis practices. Mitochondrial dysfunction is a hallmark of cancer and can...

Cite
Terra X, Ceperuelo-Mallafré V, Merma C, et al. Succinate Pathway in Head and Neck Squamous Cell Carcinoma: Potential as a Diagnostic and Prognostic Marker. Cancers (Basel). 2021;13(7)doi: 10.3390/cancers13071653.
Terra, X., Ceperuelo-Mallafré, V., Merma, C., Benaiges, E., Bosch, R., Castillo, P., Flores, J. C., León, X., Valduvieco, I., Basté, N., Cámara, M., Lejeune, M., Gumà, J., Vendrell, J., Vilaseca, I., Fernández-Veledo, S., & Avilés-Jurado, F. X. (2021). Succinate Pathway in Head and Neck Squamous Cell Carcinoma: Potential as a Diagnostic and Prognostic Marker. Cancers, 13(7), . https://doi.org/10.3390/cancers13071653
Terra, Ximena, et al. "Succinate Pathway in Head and Neck Squamous Cell Carcinoma: Potential as a Diagnostic and Prognostic Marker." Cancers vol. 13,7 (2021). doi: https://doi.org/10.3390/cancers13071653
Terra X, Ceperuelo-Mallafré V, Merma C, Benaiges E, Bosch R, Castillo P, Flores JC, León X, Valduvieco I, Basté N, Cámara M, Lejeune M, Gumà J, Vendrell J, Vilaseca I, Fernández-Veledo S, Avilés-Jurado FX. Succinate Pathway in Head and Neck Squamous Cell Carcinoma: Potential as a Diagnostic and Prognostic Marker. Cancers (Basel). 2021 Apr 01;13(7). doi: 10.3390/cancers13071653. PMID: 33916314; PMCID: PMC8037494.
Copy Download .nbib Format: NLM
EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer.

Pathology, research and practice

Pretzsch E, Lampert C, Bazhin AV, Link H, Jacob S, Guba M, Werner J, Neumann J, Angele MK, Bösch F.
PMID: 34872022
Pathol Res Pract. 2021 Nov 17;229:153688. doi: 10.1016/j.prp.2021.153688. Epub 2021 Nov 17.

BACKGROUND: In gastric cancer (GC), extracapsular growth (ECG) pattern of lymph node metastases is associated with decreased overall survival rates compared to intracapsular lymph node metastases (ICG). Epithelial-to-mesenchymal transition (EMT) plays a pivotal role in hematogenous metastatic spread. Aim...

Cite
Pretzsch E, Lampert C, Bazhin AV, et al. EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer. Pathol Res Pract. 2021;229:153688doi: 10.1016/j.prp.2021.153688.
Pretzsch, E., Lampert, C., Bazhin, A. V., Link, H., Jacob, S., Guba, M., Werner, J., Neumann, J., Angele, M. K., & Bösch, F. (2021). EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer. Pathology, research and practice, 229153688. https://doi.org/10.1016/j.prp.2021.153688
Pretzsch, Elise, et al. "EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer." Pathology, research and practice vol. 229 (2021): 153688. doi: https://doi.org/10.1016/j.prp.2021.153688
Pretzsch E, Lampert C, Bazhin AV, Link H, Jacob S, Guba M, Werner J, Neumann J, Angele MK, Bösch F. EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer. Pathol Res Pract. 2021 Nov 17;229:153688. doi: 10.1016/j.prp.2021.153688. Epub 2021 Nov 17. PMID: 34872022.
Copy Download .nbib Format: NLM
EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer.

Pathology, research and practice

Pretzsch E, Lampert C, Bazhin AV, Link H, Jacob S, Guba M, Werner J, Neumann J, Angele MK, Bösch F.
PMID: 34872022
Pathol Res Pract. 2021 Nov 17;229:153688. doi: 10.1016/j.prp.2021.153688. Epub 2021 Nov 17.

BACKGROUND: In gastric cancer (GC), extracapsular growth (ECG) pattern of lymph node metastases is associated with decreased overall survival rates compared to intracapsular lymph node metastases (ICG). Epithelial-to-mesenchymal transition (EMT) plays a pivotal role in hematogenous metastatic spread. Aim...

Cite
Pretzsch E, Lampert C, Bazhin AV, et al. EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer. Pathol Res Pract. 2021;229:153688doi: 10.1016/j.prp.2021.153688.
Pretzsch, E., Lampert, C., Bazhin, A. V., Link, H., Jacob, S., Guba, M., Werner, J., Neumann, J., Angele, M. K., & Bösch, F. (2021). EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer. Pathology, research and practice, 229153688. https://doi.org/10.1016/j.prp.2021.153688
Pretzsch, Elise, et al. "EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer." Pathology, research and practice vol. 229 (2021): 153688. doi: https://doi.org/10.1016/j.prp.2021.153688
Pretzsch E, Lampert C, Bazhin AV, Link H, Jacob S, Guba M, Werner J, Neumann J, Angele MK, Bösch F. EMT-related genes are unlikely to be involved in extracapsular growth of lymph node metastases in gastric cancer. Pathol Res Pract. 2021 Nov 17;229:153688. doi: 10.1016/j.prp.2021.153688. Epub 2021 Nov 17. PMID: 34872022.
Copy Download .nbib Format: NLM
Hospitalizations for heart failure: still major differences between East and West Germany 30 years after reunification.

ESC heart failure

Dörr M, Riemer U, Christ M, Bauersachs J, Bosch R, Laufs U, Neumann A, Scherer M, Störk S, Wachter R.
PMID: 33949148
ESC Heart Fail. 2021 Aug;8(4):2546-2555. doi: 10.1002/ehf2.13407. Epub 2021 May 04.

AIMS: Heart failure (HF) is the most common primary inpatient diagnosis in Germany. We examined temporal trends of HF hospitalization within Germany focusing on regional differences.METHODS AND RESULTS: We analysed aggregated data of more than 320 million hospitalizations in...

Cite
Dörr M, Riemer U, Christ M, et al. Hospitalizations for heart failure: still major differences between East and West Germany 30 years after reunification. ESC Heart Fail. 2021;8(4):2546-2555doi: 10.1002/ehf2.13407.
Dörr, M., Riemer, U., Christ, M., Bauersachs, J., Bosch, R., Laufs, U., Neumann, A., Scherer, M., Störk, S., & Wachter, R. (2021). Hospitalizations for heart failure: still major differences between East and West Germany 30 years after reunification. ESC heart failure, 8(4), 2546-2555. https://doi.org/10.1002/ehf2.13407
Dörr, Marcus, et al. "Hospitalizations for heart failure: still major differences between East and West Germany 30 years after reunification." ESC heart failure vol. 8,4 (2021): 2546-2555. doi: https://doi.org/10.1002/ehf2.13407
Dörr M, Riemer U, Christ M, Bauersachs J, Bosch R, Laufs U, Neumann A, Scherer M, Störk S, Wachter R. Hospitalizations for heart failure: still major differences between East and West Germany 30 years after reunification. ESC Heart Fail. 2021 Aug;8(4):2546-2555. doi: 10.1002/ehf2.13407. Epub 2021 May 04. PMID: 33949148; PMCID: PMC8318397.
Copy Download .nbib Format: NLM
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist.

CPT: pharmacometrics & systems pharmacology

Bosch R, Petrone M, Arends R, Vicini P, Sijbrands EJG, Hoefman S, Snelder N.
PMID: 34889083
CPT Pharmacometrics Syst Pharmacol. 2021 Dec 09; doi: 10.1002/psp4.12752. Epub 2021 Dec 09.

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) and dual GLP-1/glucagon receptor agonists improve glycaemic control and cause significant weight loss in patients with type 2 diabetes.

Cite
Bosch R, Petrone M, Arends R, et al. A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist. CPT Pharmacometrics Syst Pharmacol. 2021;doi: 10.1002/psp4.12752.
Bosch, R., Petrone, M., Arends, R., Vicini, P., Sijbrands, E. J. G., Hoefman, S., & Snelder, N. (2021). A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist. CPT: pharmacometrics & systems pharmacology, . https://doi.org/10.1002/psp4.12752
Bosch, Rolien, et al. "A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist." CPT: pharmacometrics & systems pharmacology vol. (2021). doi: https://doi.org/10.1002/psp4.12752
Bosch R, Petrone M, Arends R, Vicini P, Sijbrands EJG, Hoefman S, Snelder N. A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist. CPT Pharmacometrics Syst Pharmacol. 2021 Dec 09; doi: 10.1002/psp4.12752. Epub 2021 Dec 09. PMID: 34889083.
Copy Download .nbib Format: NLM
Current state of multidisciplinary treatment in cholangiocarcinoma.

Digestive diseases (Basel, Switzerland)

Ben Khaled N, Jacob S, Rössler D, Bösch F, De Toni EN, Werner J, Ricke J, Mayerle J, Seidensticker M, Schulz C, Fabritius MP.
PMID: 34695826
Dig Dis. 2021 Oct 25; doi: 10.1159/000520346. Epub 2021 Oct 25.

BACKGROUND: Cholangiocarcinoma (CCA) is a highly aggressive malignancy, and its incidence seems to be increasing over the last years. Given the high rate of irresectability at the time of initial diagnosis, new treatment approaches are important to achieve better...

Cite
Ben Khaled N, Jacob S, Rössler D, et al. Current state of multidisciplinary treatment in cholangiocarcinoma. Dig Dis. 2021;doi: 10.1159/000520346.
Ben Khaled, N., Jacob, S., Rössler, D., Bösch, F., De Toni, E. N., Werner, J., Ricke, J., Mayerle, J., Seidensticker, M., Schulz, C., & Fabritius, M. P. (2021). Current state of multidisciplinary treatment in cholangiocarcinoma. Digestive diseases (Basel, Switzerland), . https://doi.org/10.1159/000520346
Ben Khaled, Najib, et al. "Current state of multidisciplinary treatment in cholangiocarcinoma." Digestive diseases (Basel, Switzerland) vol. (2021). doi: https://doi.org/10.1159/000520346
Ben Khaled N, Jacob S, Rössler D, Bösch F, De Toni EN, Werner J, Ricke J, Mayerle J, Seidensticker M, Schulz C, Fabritius MP. Current state of multidisciplinary treatment in cholangiocarcinoma. Dig Dis. 2021 Oct 25; doi: 10.1159/000520346. Epub 2021 Oct 25. PMID: 34695826.
Copy Download .nbib Format: NLM
Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists.

Journal of cardiovascular pharmacology and therapeutics

Patel D, Busch R.
PMID: 34191622
J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):524-532. doi: 10.1177/10742484211023715. Epub 2021 Jun 30.

BACKGROUND: Atherosclerotic cardiovascular disease is a significant cause of morbidity and mortality worldwide. While use of statin therapy has improved management of lipids, an unmet need in reducing residual atherosclerotic cardiovascular disease risk and ischemic events persists. We provide...

Cite
Patel D, Busch R. Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists. J Cardiovasc Pharmacol Ther. 2021;26(6):524-532doi: 10.1177/10742484211023715.
Patel, D., & Busch, R. (2021). Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists. Journal of cardiovascular pharmacology and therapeutics, 26(6), 524-532. https://doi.org/10.1177/10742484211023715
Patel, Dhiren, and Busch, Robert. "Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists." Journal of cardiovascular pharmacology and therapeutics vol. 26,6 (2021): 524-532. doi: https://doi.org/10.1177/10742484211023715
Patel D, Busch R. Omega-3 Fatty Acids and Cardiovascular Disease: A Narrative Review for Pharmacists. J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):524-532. doi: 10.1177/10742484211023715. Epub 2021 Jun 30. PMID: 34191622; PMCID: PMC8547235.
Copy Download .nbib Format: NLM
A novel immune-related gene signature predicting survival in sarcoma patients.

Molecular therapy oncolytics

Ren H, Bazhin AV, Pretzsch E, Jacob S, Yu H, Zhu J, Albertsmeier M, Lindner LH, Knösel T, Werner J, Angele MK, Bösch F.
PMID: 35024438
Mol Ther Oncolytics. 2021 Dec 09;24:114-126. doi: 10.1016/j.omto.2021.12.007. eCollection 2022 Mar 17.

Sarcomas are a heterogeneous group of rare mesenchymal tumors. The migration of immune cells into these tumors and the prognostic impact of tumor-specific factors determining their interaction with these tumors remain poorly understood. The current risk stratification system is...

Cite
Ren H, Bazhin AV, Pretzsch E, et al. A novel immune-related gene signature predicting survival in sarcoma patients. Mol Ther Oncolytics. 2021;24:114-126doi: 10.1016/j.omto.2021.12.007.
Ren, H., Bazhin, A. V., Pretzsch, E., Jacob, S., Yu, H., Zhu, J., Albertsmeier, M., Lindner, L. H., Knösel, T., Werner, J., Angele, M. K., & Bösch, F. (2022). A novel immune-related gene signature predicting survival in sarcoma patients. Molecular therapy oncolytics, 24114-126. https://doi.org/10.1016/j.omto.2021.12.007
Ren, Haoyu, et al. "A novel immune-related gene signature predicting survival in sarcoma patients." Molecular therapy oncolytics vol. 24 (2022): 114-126. doi: https://doi.org/10.1016/j.omto.2021.12.007
Ren H, Bazhin AV, Pretzsch E, Jacob S, Yu H, Zhu J, Albertsmeier M, Lindner LH, Knösel T, Werner J, Angele MK, Bösch F. A novel immune-related gene signature predicting survival in sarcoma patients. Mol Ther Oncolytics. 2021 Dec 09;24:114-126. doi: 10.1016/j.omto.2021.12.007. eCollection 2022 Mar 17. PMID: 35024438; PMCID: PMC8718575.
Copy Download .nbib Format: NLM
AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications.

BMC infectious diseases

Notter J, Seiffert SN, Zimmermann-Kogadeeva M, Bösch A, Wenger R, Strahm C, Frischknecht M, Livermore DM, Babouee Flury B.
PMID: 34991516
BMC Infect Dis. 2022 Jan 06;22(1):33. doi: 10.1186/s12879-021-07000-y.

BACKGROUND: Data on antimicrobial resistance mechanisms are scanty for Cedecea spp., with very variable antibiotic resistance patterns documented. Here we report the first in vivo resistance evolution of a C. davisae clinical isolate in a patient with a complex...

Cite
Notter J, Seiffert SN, Zimmermann-Kogadeeva M, et al. AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications. BMC Infect Dis. 2022;22(1):33doi: 10.1186/s12879-021-07000-y.
Notter, J., Seiffert, S. N., Zimmermann-Kogadeeva, M., Bösch, A., Wenger, R., Strahm, C., Frischknecht, M., Livermore, D. M., & Babouee Flury, B. (2022). AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications. BMC infectious diseases, 22(1), 33. https://doi.org/10.1186/s12879-021-07000-y
Notter, Julia, et al. "AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications." BMC infectious diseases vol. 22,1 (2022): 33. doi: https://doi.org/10.1186/s12879-021-07000-y
Notter J, Seiffert SN, Zimmermann-Kogadeeva M, Bösch A, Wenger R, Strahm C, Frischknecht M, Livermore DM, Babouee Flury B. AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications. BMC Infect Dis. 2022 Jan 06;22(1):33. doi: 10.1186/s12879-021-07000-y. PMID: 34991516; PMCID: PMC8734214.
Copy Download .nbib Format: NLM
Publisher Correction: Large Chinese land carbon sink estimated from atmospheric carbon dioxide data.

Nature

Wang J, Feng L, Palmer PI, Liu Y, Fang S, Bösch H, O'Dell CW, Tang X, Yang D, Liu L, Xia C.
PMID: 33230335
Nature. 2020 Dec;588(7837):E19. doi: 10.1038/s41586-020-2986-1.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Wang J, Feng L, Palmer PI, et al. Publisher Correction: Large Chinese land carbon sink estimated from atmospheric carbon dioxide data. Nature. 2020;588(7837):E19doi: 10.1038/s41586-020-2986-1.
Wang, J., Feng, L., Palmer, P. I., Liu, Y., Fang, S., Bösch, H., O'Dell, C. W., Tang, X., Yang, D., Liu, L., & Xia, C. (2020). Publisher Correction: Large Chinese land carbon sink estimated from atmospheric carbon dioxide data. Nature, 588(7837), E19. https://doi.org/10.1038/s41586-020-2986-1
Wang, Jing, et al. "Publisher Correction: Large Chinese land carbon sink estimated from atmospheric carbon dioxide data." Nature vol. 588,7837 (2020): E19. doi: https://doi.org/10.1038/s41586-020-2986-1
Wang J, Feng L, Palmer PI, Liu Y, Fang S, Bösch H, O'Dell CW, Tang X, Yang D, Liu L, Xia C. Publisher Correction: Large Chinese land carbon sink estimated from atmospheric carbon dioxide data. Nature. 2020 Dec;588(7837):E19. doi: 10.1038/s41586-020-2986-1. PMID: 33230335.
Copy Download .nbib Format: NLM
A novel immune-related gene signature predicting survival in sarcoma patients.

Molecular therapy oncolytics

Ren H, Bazhin AV, Pretzsch E, Jacob S, Yu H, Zhu J, Albertsmeier M, Lindner LH, Knösel T, Werner J, Angele MK, Bösch F.
PMID: 35024438
Mol Ther Oncolytics. 2021 Dec 09;24:114-126. doi: 10.1016/j.omto.2021.12.007. eCollection 2022 Mar 17.

Sarcomas are a heterogeneous group of rare mesenchymal tumors. The migration of immune cells into these tumors and the prognostic impact of tumor-specific factors determining their interaction with these tumors remain poorly understood. The current risk stratification system is...

Cite
Ren H, Bazhin AV, Pretzsch E, et al. A novel immune-related gene signature predicting survival in sarcoma patients. Mol Ther Oncolytics. 2021;24:114-126doi: 10.1016/j.omto.2021.12.007.
Ren, H., Bazhin, A. V., Pretzsch, E., Jacob, S., Yu, H., Zhu, J., Albertsmeier, M., Lindner, L. H., Knösel, T., Werner, J., Angele, M. K., & Bösch, F. (2022). A novel immune-related gene signature predicting survival in sarcoma patients. Molecular therapy oncolytics, 24114-126. https://doi.org/10.1016/j.omto.2021.12.007
Ren, Haoyu, et al. "A novel immune-related gene signature predicting survival in sarcoma patients." Molecular therapy oncolytics vol. 24 (2022): 114-126. doi: https://doi.org/10.1016/j.omto.2021.12.007
Ren H, Bazhin AV, Pretzsch E, Jacob S, Yu H, Zhu J, Albertsmeier M, Lindner LH, Knösel T, Werner J, Angele MK, Bösch F. A novel immune-related gene signature predicting survival in sarcoma patients. Mol Ther Oncolytics. 2021 Dec 09;24:114-126. doi: 10.1016/j.omto.2021.12.007. eCollection 2022 Mar 17. PMID: 35024438; PMCID: PMC8718575.
Copy Download .nbib Format: NLM
Showing 217 to 228 of 228 entries